North East Innovation Lab celebrates two year anniversary supporting the development of cutting-edge diagnostics

The North East Innovation Lab is celebrating a two-year milestone birthday and has expanded its work in accelerating the development of diagnostics for a range of virus and health threats.


Based at The Biosphere in Newcastle Helix, the facility is part of Newcastle Hospitals and plays a key role in bringing new approaches and diagnostics to mainstream use.


The team supports developers with testing and improving their technologies, which includes conducting independent performance evaluations and validations for new and emerging diagnostics; methodology and protocol development and bespoke sample collection. 


The lab’s well-stocked biobank holds over 22,000 carefully categorised clinical samples, including blood, serum and saliva, offering clients access to the materials needed to test products and devices. 


Since opening, the lab has engaged with over 100 test developers from industry, academia and the NHS, and worked on over 45 projects with 21 companies across the globe from the UK to the USA and China to Australia.


Dr John Tyson, head of the innovation lab, said:


“We have been able to build on the fast-moving progress and innovation in diagnostics that came through the pandemic and have expanded our portfolio to include supporting

diagnostics across a range of diseases, ranging from sepsis and cancer.


“Our core aim is to accelerate the development of new tests so that they are high quality, convenient and can be widely accessed by those who need them.


“We have strong expertise in the evaluation of diagnostics and facilitating the accelerated development of innovative products helping them get into wider use. Wider access to better tests has the potential to improve patient and population health, whilst supporting the reduction of health inequalities.”


Diagnostics have a huge role to play in improving health for patients offering the opportunity to both diagnose disease and guide treatment. 


The lab is working on projects to develop diagnostics which can personalise treatment for conditions such as breast cancer and urinary tract infections for the elderly.


The team are also involved in validating a system which uses artificial intelligence to help clinicians and scientists to identify pathogens such as MRSA, group A Streptococcus (group A strep) which causes scarlet fever.  


The lab’s team of NHS scientists specialise in molecular biology, methodology and clinical research, with a client base including UK and international organisations, from university spin-outs to large multi-national corporations.


To find out more visit the website or watch this short film video.





New AbC-19™ COVID-19 antibody test developed by Abingdon Health and the UK-RTC

As demand for rapid testing continues to accelerate at an unprecedented level, our response to assis...

Read More >

Shift to Paradigm™ Low-Retention Tips

A New Standard of Excellence in Your Application

Read More >

The Future of Pathology: Landmark initiative to spark conversation between pathology community and healthcare leaders

International panel of pathologists drive forward-thinking agenda on role of pathology in transformi...

Read More >

Improved Nucleic Acid Isolation

New QuickGene Range for DNA & RNA Extraction- Now with Automated Option

Read More >


A new exhibition at the Science Museum, London will feature an invention from the Oxford area which ...

Read More >

Biofortuna closes £1.6M funding round

Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract m...

Read More >